The ABL kinase inhibitor imatinib causes phenotypic changes and lethality in adult Schistosoma japonicum
Schistosomiasis caused by different species of schistosome parasites is one of the most debilitating helminthic diseases of humans worldwide. For decades, chemotherapy is the main method of controlling schistosomiasis. However, the fear of drug resistance has motivated the search for alternatives. It has been demonstrated that the ABL kinase inhibitor imatinib affected the development and survival of Schistosoma mansoni in vitro; however, there is still lack of information on whether imatinib also affects other schistosome species such as Schistosoma japonicum. In the present study, the anti-schistosomal potency of imatinib on adult S. japonicum was investigated in vitro, and the results showed that imatinib had a significant impact on various physiological processes of S. japonicum adult worms. Besides its negative effects on worm motility, pairing stability, and gonad development, imatinib caused pathological changes in the gastrodermis as well as the death of the parasite. Our findings suggest that imatinib is an intriguing candidate for further development as an option to fight S. japonicum.
KeywordsImatinib ABL kinases Schistosoma japonicum Development In vitro culture
- S. japonicum
- S. mansoni
Protein tyrosine kinases
Chronic myelogenous leukemia
Proto-oncogene receptor tyrosine kinase
Platelet-derived growth factor receptors
Confocal laser scanning microscopy
Conceived and designed the experiments: SH, CGG, and MH. Performed the experiments: XS, LZ, MM, TZ, and LL. Analyzed the data: XS, SH, LZ, CGG, and MH. Contributed reagents/materials/analysis tools: RF, YQZ, and JLZ. Wrote the paper: XS, SH, LZ, CGG, and MH. All authors read and approved the final manuscript.
This work was supported by grants from the National Key Basic Research Program (973 program) of China (grant no. 2015CB150300) and the Fundamental Research Funds for the Central Universities (grant no. 2662017PY084) to MH and the Huazhong Agricultural University Scientific & Technological Self Innovation Foundation (Program no. 2015RC005) to MH, RF, YQZ, and JLZ.
Compliance with ethical standards
Ethical approval and consent to participate
The conduct and procedures involving animal experimentation in this study were approved by the Scientific Ethics Committee of Huazhong Agricultural University (HZAUMO-2017-024) according to the regulations for the Administration of Affairs Concerning Experimental Animals of Hubei Province.
Conflict of interests
The authors declare that they have no competing interests.
- Abdulla MH, Ruelas DS, Wolff B, Snedecor J, Lim KC, Xu F, Renslo AR (2009) Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis 3(7):e478. https://doi.org/10.1371/journal.pntd.0000478 CrossRefGoogle Scholar
- Beckmann S (2012) Protein kinases as potential targets for novel anti-schistosomal strategies. Curr Pharm Des 18(24):3579–3594Google Scholar
- Beckmann S, Quack T, Burmeister C, Buro C, Long T, Dissous C, Grevelding CG (2010) Schistosoma mansoni: signal transduction processes during the development of the reproductive organs. Parasitol 137(03):497Google Scholar
- Beckmann S, Long T, Scheld C, Geyer R, Caffrey C, Grevelding CG (2014) Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor imatinib. Int J Parasitol Drugs Drug Resist 4(3):287–295. https://doi.org/10.1016/j.ijpddr.2014.07.005 CrossRefGoogle Scholar
- Buro C, Beckmann S, Oliveira KC, Dissous C, Cailliau K, Grevelding CG (2014) Imatinib treatment causes substantial transcriptional changes in adult Schistosoma mansoni in vitro exhibiting pleiotropic effects. PLoS Negl Trop Dis 8(6):e2923. https://doi.org/10.1371/journal.pntd.0002923 CrossRefGoogle Scholar
- Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343–3356Google Scholar
- Grover JK, Vats V, Uppal G, Yadav S (2001) Anthelmintics: a review. Trop Gastroenterol 22(4):180–189Google Scholar
- Han ZG, Brindley PJ, Wang SY, Chen Z (2009) Schistosoma genomics: new perspectives on schistosome biology and host-parasite interaction. Annu Rev Genomics Hum Genet 10:211–240. https://doi.org/10.1146/annurev-genom-082908-150036 CrossRefGoogle Scholar
- Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnke T (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022–4028. https://doi.org/10.1182/blood-2007-10-116475 CrossRefGoogle Scholar
- Neves RH, de Lamare Biolchini C, Machado-Silva JR, Carvalho JJ (2005) A new description of the reproductive system of Schistosoma mansoni (Trematoda: Schistosomatidae) analyzed by confocal laser scanning microscopy. Parasitol Res 95(1):43–49. https://doi.org/10.1007/s00436-004-1241-2 CrossRefGoogle Scholar
- O’Connell EM, Bennuru S, Steel C, Dolan MA, Nutman TB (2015) Targeting filarial Abl-like hinases: orally available, food and drug administration-approved tyrosine kinase inhibitors are microfilaricidal and macrofilaricidal. J Infect Dis 212(5):684–693. https://doi.org/10.1093/infdis/jiv065 CrossRefGoogle Scholar
- Wang J, Li Y, Zhou SL (1987) An observation of praziquantel effecting on the activity and survival of hepatic-portal-phase Schistosomulae of Schistosoma japonicum in vitro. Acta AcadMed Hebei 18:338–342 [in Chinese]Google Scholar
- WHO (2017) Schistosomiasis and soil-transmitted helminthiases: number of people treated in 2016. Wkly Epidemiol Rec 92(49):749–760Google Scholar